Complete inhalation products that shorten time to market

NEWS

Upcoming events

BIO-Europe Spring Digital
2021, 22-25 March

Stockholm Corporate Finance 13:e Life Science-seminarium
23 och 24 mars 2021
Tid: 07.30-12.15
https://www.lyyti.fi/reg/scf-life-science-seminarium-2021

Respiratory Drug Delivery Viritual
2021, 4-7 May

Introduction to Iconovo

Johan Wäborg, CEO. Aktiedagen i Lund 17 feb, 2021 ( in Swedish)

PRODUCTS

Four differentiated technical platforms, available for customization

Iconovo offers the development of inhalation products — inhaler devices and dry powder formulation — and assists in clinical trials and registration. We also offer proprietary generic drugs. The inhalation platforms are primarily intended for asthma and chronic obstructive pulmonary disease (COPD) treatment.

Learn more…

SERVICES

Seeking a fast and safe way to reach the market?

We work with international generic drug companies and pharmaceutical companies that lack the expertise, resources and/or time to develop the product themselves. Our development time is shorter and consequently more cost-effective since we have ready-to-use platforms with inhalation products that can be modified for a specific drug.

Learn more…

CAPABILITIES

A unique combination of engineering and pharmaceutical expertise

Iconovos highly skilled employees offers a comprehensive service package including device design, formulation development, analytical testing and documentation. Iconovo has build its own state-of-the-art laboratories for analysis, development and characterization of powder formulations.
Learn more…

Seven steps to market

Our R&D shortens the time to product launch,
and reduces your project risk and development cost

  • STEP ONE: Iconovo

     

    • Inhaler device development
    • Models
    • Prototypes

  • STEP TWO: Iconovo

     

    Optimization for Manufacturing

  • STEP THREE: Iconovo

     

    Optimization with model inhalation powder

  • STEP FOUR: Iconovo

     

    Formulation development

  • STEP FIVE: Iconovo

     

    Inhaler device and formulation optimization

  • STEP SIX: Iconovo with customer

     

    • Technology transfer
    • Support and advice to clinical trials and registration

  • STEP SEVEN: Customer

     

    • Commercial Manufacturing
    • Marketing and sales

Read more about our customer collaborations

Iconovo – development commitments
with partners world wide

Development of a generic Symbicort product (budesonide/formoterol) primarily for the European market together with Amneal.

Development of a specific generic product in ICOres involving both the development of the dry powder formulation and adaptations to the multi-dose dry powder inhaler ICOres.

Stevanato Group, an Italian medical device manufacturer, will manufacture, distribute and sell the inhaler device ICOcap globally. The inhaler is developed by Iconovo.

Iconovo participates in a scientific research and development project with McMaster University in Canada. The project aims to develop the next generation TB vaccine as a dry powder inhaler that is stable in room temperature.

Pilot and proof-of-concept study of four products in two inhaler platforms from Iconovo. The products are for the treatment of asthma and COPD intended for the Japanese market.

Want to know when we got news on our platforms? Sign up for our press releases now!